Published in final edited form as:

Nat Med. 2017 January 06; 23(1): 18–27. doi:10.1038/nm.4241.

T memory stem cells in health and disease

Luca Gattinoni¹, Daniel E. Speiser², Mathias Lichterfeld³, and Chiara Bonini⁴

¹Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. ²Department of

Oncology, Ludwig Cancer Research, Lausanne University Hospital, Lausanne, Switzerland

³Division of Infectious Diseases, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA ⁴Experimental Hematology Unit, Division of Immunology Transplantation and Infectious Diseases, Leukemia Unit, Vita-Salute San Raffaele University and San Raffaele Scientific Institute, Milan, Italy

Abstract

T memory stem cells (T_{SCM}) are a rare subset of memory lymphocytes endowed with the stem cell-like ability to self-renew and the multipotent capacity to reconstitute the entire spectrum of memory and effector subsets. Cumulative evidence in mice, non-human primates and humans indicates that T_{SCM} are minimally differentiated cells at the apex of the hierarchical system of memory T lymphocytes. Here we describe emerging findings demonstrating that T_{SCM}, owing to their extreme longevity and robust potential for immune reconstitution, are central players in many physiological and pathological human processes. We also discuss how T_{SCM} stemness could be therapeutically leveraged to enhance the efficacy of vaccines and adoptive T-cell therapies for cancer and infectious diseases or, conversely, disrupted to treat T_{SCM}-driven and sustained diseases such as autoimmunity, adult T-cell leukemia, and HIV-1.

Graphical Abstract

Correspondence to: Luca Gattinoni (gattinoli@mail.nih.gov), Daniel E. Speiser (doc@dspeiser.ch), Mathias Lichterfeld (MLICHTERFELD@mgh.harvard.edu) or Chiara Bonini (bonini.chiara@hsr.it).

Disclosure of Conflicts of interest:

All authors declare that they have no competing interests.

“δὲς γὰρ τὸν αὐτόν, ὥστε καὶ κτείνειν, οὐκ ἐπελάμβανεν.”

“For this disease never took any man the second time so as to be mortal.”

Thucydides, The History of the Peloponnesian War.

Translation by Thomas Hobbes

Immunological memory – the ability to remember and respond rapidly and more vigorously to subsequent encounters with a pathogen – has long been recognized in human history. The first documentation of immunological memory was provided by the Greek historian, Thucydides, who vividly described the plague that struck the city of Athens in 430 BC recounting that “*this disease never took any man the second time*”¹. It took us more than two millennia to gain insights into the cellular basis of the immune system and to understand that immunological memory is a fundamental property of the adaptive immunity conveyed by B and T lymphocytes².

Despite the enormous progress in our understanding of basic aspects of T-cell immunity, the ontogeny of memory T cells remains a matter of active debate^{3,4}. It is clear, however, that immunological memory and protective immunity can last several decades and perhaps a lifetime even in the absence of re-exposure to the pathogen^{5,6}. This astonishing stability of T-cell memory in spite of the high cellular turnover characterizing the immune responses and the lack of replenishment of antigen-specific T cells from hematopoietic stem cells (HSCs) due to constraints imposed by stochastic recombination of the T-cell receptor (TCR) and thymic involution, has sparked the idea that T-cell immunity could be maintained *via* stem cell-like memory T cells⁷. Over the past decade, the realization that memory T cells share a core transcriptional signature with HSCs⁸ and display functional properties found in stem cells, such as the capacity to divide asymmetrically to generate cellular heterogeneity⁹, has further strengthened the view that T cells, akin to all somatic tissues, may be hierarchically organized and sustained by antigen-specific T memory stem cells¹⁰.

In this Review, we outline emerging findings demonstrating that a subset of minimally differentiated memory T cells behave as antigen-specific adult stem cells. We also discuss recent evidence placing these T memory stem cells (T_{SCM}) at center stage in many physiological and pathological human processes. Finally, we highlight ongoing efforts aiming either at harnessing the therapeutic potential of T_{SCM} for adoptive immunotherapies or conversely at destabilizing the T_{SCM} compartment to eliminate drug-resistant viral reservoirs or treat adult T-cell leukemia and autoimmune diseases. The conceptual work and key discoveries that have shaped this field of investigation are summarized in the Timeline.

The discovery of T_{SCM} cells

Advances in multiparameter flow cytometry over the last 20 years have allowed us to dissect the heterogeneity of the T-cell compartment with ever-increasing precision¹¹. In a seminal study, van Lier and colleagues identified human naïve, memory, and effector T-cell subsets based on the combinatorial expression of CD27 and CD45RA, with naïve cells expressing both molecules, whereas memory and effector cells expressing only CD27 or CD45RA, respectively¹². Subsequent work by Sallusto *et al.*¹³ revealed the presence of two major functional subsets within the CD45RA⁺ memory T-cell pool: central memory T cells (T_{CM}), which express the lymph node homing molecules CCR7 and CD62L and have limited effector functions, and CCR7⁺CD62L⁺ effector memory T cells (T_{EM}), which preferentially traffic to peripheral tissues and mediate rapid effector functions.

The idea that memory T cells may not solely be confined to the CD45RA⁺ T-cell compartment, but may also be present within what was considered to be an exclusive naïve T-cell realm, began to take shape following the identification in mice of a novel memory T-cell population characterized by a naïve-like phenotype but expressing high amounts of stem cell antigen-1 (SCA-1) and the memory markers interleukin-2 receptor β (IL-2R β) and chemokine C-X-C motif receptor 3 (CXCR3)¹⁴. These cells were termed T_{SCM} based on the observation that they were capable of sustaining graft-versus-host disease (GVHD) upon serial transplantation in allogeneic hosts and that they could reconstitute the full diversity of memory and effector T-cell subsets while maintaining their own pool size through self-renewal¹⁴. Identifying the human counterpart of T_{SCM}, however, has not been straightforward mainly due to the lack of a human ortholog of SCA-1, the prototypical marker of mouse T_{SCM}. Though it was known that a significant fraction of long-lived antigen-specific CD8⁺ and CD4⁺ memory T cells displayed a naïve-like phenotype (CD45RA⁺CCR7⁺CD27⁺) years after infection with EBV¹⁵ or vaccination with attenuated smallpox or yellow fever (YF) viruses^{16,17}, a precise set of surface markers to pinpoint this elusive memory phenotype in humans was missing. The breakthrough came with the demonstration that mouse T_{SCM} could be successfully generated *in vitro* from naïve precursors by activating the WNT- β -catenin signaling pathway using the WNT ligand, WNT3A, or inhibitors of glycogen synthase kinase-3 β ¹⁸. Translated to humans, this strategy has recently allowed the identification of human T_{SCM}¹⁹. Similar to their murine counterparts, human and non-human primate (NHP) T_{SCM} are clonally expanded cells expressing a largely naïve-like phenotype in conjunction with a core of memory markers such as CD95, CXCR3, IL-2R β , CD58 and CD11a^{19,20}. These cells represent a small fraction of circulating T lymphocytes ($\approx$ 2–3%). Interestingly, the frequency of circulating T_{SCM} does not significantly vary with age²¹, but it appears to be heritable and associated with single nucleotide polymorphisms at a genetic locus containing CD95²², suggesting a potential role of FAS signaling in the regulation of T_{SCM} homeostasis. T_{SCM} exhibit all the defining properties of memory cells, including a diluted content of TCR excision circles, the ability to rapidly proliferate and release inflammatory cytokines in response to antigen re-exposure, and a dependence on IL-15 and IL-7 for homeostatic turnover^{19,23}. Despite being functionally distinct from naïve T cells, they share similar recirculation patterns and distribution *in vivo* as evidenced by detailed compartmentalization studies in NHP²⁴. For

instance, T_{SCM} are found more abundantly in lymph nodes compared to the spleen and bone marrow and are virtually absent from peripheral mucosae²⁴. Thus, T_{SCM} represent a subset of minimally differentiated T cells characterized by phenotypic and functional properties bridging naïve and conventional memory cells (Fig. 1).

T_{SCM} cells: Evidence of stemness

The concept of stemness embraces the capacity both to self-renew and to generate the entire spectrum of more differentiated cells²⁵. When the existence of a stem cell pool of memory T lymphocytes was initially postulated by Fearon and colleagues⁷, the authors pointed to T_{CM} as putative T memory stem cells. This assumption was based on the evidence that T_{CM} are less differentiated than T_{EM} and effector cells, as shown by their longer telomeres and lower expression of perforin, granzymes and other effector molecules¹³. Furthermore, it was intuitive to assume that the pool of T memory stem cells should be confined in lymph nodes and secondary lymphoid organs, and T_{CM} were, at that time, the only antigen-experienced T cells known to express CCR7 and CD62L. The notion that T_{CM} might function as T memory stem cells was further supported by subsequent findings demonstrating that T_{CM} have superior immune reconstitution capacity and a greater ability to persist *in vivo* than T_{EM}²⁶. Recent clonogenic experiments in mice based on single cell serial transfer have formally demonstrated the ability of murine T_{CM} to self-renew and generate T_{EM} and effector progenies *in vivo*^{27,28}. Strikingly, T_{EM} were unable to serially reconstitute the host even when transferred at 100-fold higher numbers, showing a limited capacity for self-renewal. Although these experiments did not evaluate T_{SCM}, these results, combined with that of sophisticated experiments tracking T cell fates in mice based on genetic barcoding²⁹ and on single naïve T-cell transfer³⁰, provided strong support for the progressive model of T-cell differentiation originally developed by Sallusto and Lanzavecchia³¹. Indeed, three separate models have been proposed to explain memory T-cell differentiation³: according to the first 2 models memory T cells originate from effectors either after²⁶ or before³² the peak of T-cell expansion. The progressive differentiation model, on the contrary, suggests that memory T cells are derived directly from naïve lymphocytes upon priming, and further differentiate into shorter-lived effector subsets in a hierarchical differentiation tree, similar to that of other organ systems³¹ (Fig. 1). Using hematopoietic stem cell transplantation (HSCT) from haploidentical donors as a model system to study T-cell differentiation, two independent groups have recently showed at polyclonal, antigen-specific, and clonal levels, that human T_{SCM} differentiate directly from naïve precursors, emerging early upon *in vivo* priming^{33,34}. By multiparametric flow cytometry and TCR sequencing of individual T lymphocytes it was possible to trace and quantify, at the clonal level, the *in vivo* differentiation landscapes of transferred naïve and antigen-experienced T cells, highlighting T_{SCM} as privileged players in the diversification of naïve cells upon priming^{33,34}. Indeed, discrete T-cell subsets traced across HSCT behaved preferentially within a progressive framework of differentiation. Notably, only naïve T cells and T_{SCM} were able to reconstitute the entire heterogeneity of memory T-cell subsets, including T_{SCM}³³. A fraction of originally T_{EM} reverted to a T_{CM} phenotype³³. By contrast, only a very limited number of T_{CM} and T_{EM} converted to T_{SCM}³³. Echoing these findings, the transfer of genetically-modified virus-specific T cells reconstituted the full diversity of the T-cell memory compartment – inclusive of T_{SCM}, T_{CM}

and T_{EM} – only when T_{SCM} were present within the infused cell product³⁵. Altogether these results strengthen earlier *in vitro* observations in human¹⁹ and NHP²⁴ showing that the potential to form diverse progeny is progressively restricted proceeding from T_{SCM} to T_{CM} and T_{EM}. Thus, granting some level of plasticity to the system, these data point to a progressive model of T-cell differentiation, in which T_{SCM} are at the apex of the hierarchical tree. In line with this concept, the gene expression profile of human T-cell subsets partitions T_{SCM} with antigen-experienced T cells, and places them at a hierarchically superior level than T_{CM}^{19,23,36,37}.

The concept of stemness also involves self-renewal and implicates long-term persistence²⁵. The long-term persisting ability of T_{SCM} and other antigen-experienced T cells cannot be easily addressed in humans, since naïve T cells are continuously generated, and several antigenic contacts might occur after the initial encounter. Longitudinal monitoring of genetically-engineered lymphocytes infused as antigen-experienced cells and distinguishable from endogenous lymphocytes thanks to the retroviral integration and transgene expression, has recently allowed the tracking of single T-cell clonotypes over time. In patients affected by ADA-SCID, genetically-engineered T_{SCM} persisted and preserved their precursor potential for decades³⁸. In leukemic patients treated with haploidentical HSCT and donor lymphocytes retrovirally transduced to express a suicide gene, engineered lymphocytes were traced for up to 14 years³⁵. This study revealed that the extent of expansion and the amount of persisting gene-marked T cells tightly correlate with the number of T_{SCM} infused, indicating that this subset of memory cells is endowed with enhanced proliferative potential, immune reconstitution capacity and longevity³⁵. Interestingly, the same observation has been reported in a clinical trial based on the infusion of autologous T cells genetically-engineered to express a chimeric antigen receptor (CAR)³⁹, underscoring that this phenomenon is not confined to the HSCT model. In patients treated with suicide gene therapy, by combining T-cell sorting with sequencing of integration, TCR α and TCR β clonal markers, it was possible to show that dominant long-term T-cell clones preferentially originate from infused T_{SCM} and to a lesser degree from T_{CM} clones³⁵. Together, these results indicate that human T_{SCM} have an exceptional capacity to persist long-term. Similar conclusions were reached by monitoring T-cell subset dynamics in NHP infection models²⁴ and HIV-1 patients undergoing antiretroviral therapy (ART)⁴⁰, in which antigen load and time of antigen exposure can be precisely controlled. Taking advantage of the peculiar biology of the Tat-specific epitope TL8, which uniformly undergoes escape mutation within 4–5 weeks after Simian Immunodeficiency Virus (SIV) infection, Lugli *et al.*²⁴ investigated the persistence of different memory T-cell subsets in the virtual absence of any antigen perturbation. In this setting, T_{SCM} were able to persist at unchanged levels for up to 70 days after infection, whereas T_{CM} and T_{EM} contracted 10-fold and 100-fold, respectively²⁴. Likewise, pharmacological antigen withdrawal in ART-treated HIV-1 patients was associated with a decline of HIV-1-specific T_{EM} and terminally differentiated effector cells (T_{TE}), whereas T_{SCM} were restored and even expanded under these conditions⁴⁰. Mirroring these findings, YF-specific T-cell subsets declined after vaccination with attrition rates progressively increasing along with a differentiation from T_{CM} to T_{EM} and T_{TE}³⁶. Remarkably, the frequency of YF-specific T_{SCM} was stably maintained even 25 years after vaccination³⁶. Taken together, this series of studies provides compelling evidence that

human T_{SCM} are generated directly from naïve lymphocytes and are endowed with long-term self-renewal capacity and multipotency.

T_{SCM} cells in antimicrobial immune defense and after vaccination

Human T_{SCM} have been increasingly identified in acute and chronic infections caused by a variety of pathogens, including viruses, bacteria and parasites^{19,35,36,40–42}. These results demonstrate that T_{SCM} are commonly generated during natural immune responses against foreign pathogens, but the underlying mechanisms remain poorly understood. Human studies are limited in that the exact time of infection is usually unknown, making it difficult to study T-cell priming and kinetics. By contrast, active vaccination offers the possibility to induce an immune response in a supervised fashion. Smallpox and YF vaccines are particularly suitable models of human primary acute viral infection as they consist of live attenuated, replication competent viruses capable of inducing strong immune responses with consequent clinical symptoms⁴³. Using YF vaccination as model system, the kinetics of T_{SCM} formation and long-term maintenance have recently been studied in great detail³⁶. Consistent with findings from studies of SIV infection in NHP²⁴, YF-specific T_{SCM} were detectable at early time points after vaccination when the immune response was dominated by effector T cells³⁶. These T_{SCM} persisted at stable levels, becoming the major YF-specific memory T-cell population in the circulation decades after the initial immunization³⁶. Considering that YF vaccination provides life-long protection⁴³, it is reasonable to assume that T_{SCM} play a central role in the maintenance of long-term T-cell memory.

The presence of a relevant pool of T_{SCM} might also be essential for the control of persisting infections, in which effector T cells undergoing functional exhaustion and replicative senescence need to be continuously replenished by less-differentiated T-cell subsets^{44–46}. Interestingly, recent studies in chronic viral^{40,47} and parasitic infections⁴² have shown the existence of a negative correlation between the severity of disease and the frequency of circulating T_{SCM}. It is unclear whether these observations result from the inability of T_{SCM} to be maintained under conditions of strong inflammation and high antigenic load, or vice versa, the lack of physiological numbers of T_{SCM} impairs the ability of the immune system to keep the infection in check. However, emerging findings suggest that T_{SCM} are a fundamental pillar of immune homeostasis as high levels of infection and subsequent functional perturbation of the T_{SCM} compartment have been linked to the development of symptomatic immune deficiency following SIV and HIV-1 infections^{48,49}. Indeed, high quantities of SIV DNA were found in CD4⁺ T_{SCM} from rhesus macaques, who typically develop an AIDS-like clinical picture when left untreated, but not in CD4⁺ T_{SCM} from SIV-infected sooty mangabeys, a group of NHP who are refractory to clinical or laboratory signs of immune deficiency even when high levels of virus circulate in the peripheral blood^{48,50,51}. Resonating with this observation, viremic non-progressors – a rare group of untreated HIV-1 patients, who develop high levels of HIV-1 replication in the absence of clinical immune deficiency – exhibit reduced levels of HIV-1 DNA in CD4⁺ T_{SCM} in comparison to HIV-1 patients with ordinary rates of disease progression, who instead show high amounts of HIV-1 infected T_{SCM} despite a relative depletion of the total CD4⁺ T_{SCM} compartment⁴⁹. Altogether these results underscore a critical function of T_{SCM} in sustaining long-lasting cellular immunity against acute and chronic microbial infections.

Given the pivotal role of T_{SCM} in maintaining life-long immunological memory, it would be desirable to develop vaccines capable of inducing significant numbers of T_{SCM}. The majority of clinical vaccine formulations designed to stimulate CD8⁺ T-cell-mediated immunity induce predominantly T_{EM}, with only little emergence of memory cells^{52,53}. These vaccines are generally poorly efficient and rarely protective compared to those inducing protective antibodies^{2,54}. Indeed, current T-cell vaccines appear unable to trigger mechanisms that are key for the development of memory T cells, including optimal signaling *via* the TCR and induction of appropriate metabolic programs, transcription factors, and chromatin reorganization⁵⁵. Considering that the activation of CD8⁺ T cells under conditions of low-level inflammation enhances memory cell formation, one may consider that novel vaccines should preferentially activate T cells without triggering the excessive release of pro-inflammatory cytokines⁵⁶. It is however debatable whether optimal generation of memory T cells requires the avoidance of effector cell differentiation. This is illustrated by the fact that natural infections generate sound memory T-cell responses, including T_{SCM}, despite initial predominance of effector cells⁴³. Much work remains to be done in this area, however, the induction of T_{SCM} by novel vaccines should not be at the expense of more differentiated T_{EM} and tissue-resident memory cells, which assure immediate protection at the entry site of re-infection in peripheral tissues^{57–59}. Ideally, new vaccines will be able to recreate the large heterogeneity of memory cells, including long-lived T_{SCM}, that human pathogens and their pathophysiological properties induce *in vivo*^{60,61}.

T_{SCM} cells in human diseases

The complex biology of T_{SCM} can make it difficult to discriminate between their protective and pathogenic effects because the very characteristics that enable T_{SCM} to represent the backbone of life-long cellular immunity under physiologic conditions may empower these cells to drive disease pathogenesis⁶². This seems particularly relevant in the setting of a growing list of immune-mediated diseases associated with aberrant and autoreactive memory T cells. For instance, recent correlative studies have suggested an increased frequency and activation state of CD8⁺ T_{SCM} in individuals with aplastic anemia, a disease mediated by autoreactive cytotoxic T cells targeting hematopoietic progenitors⁶³. Moreover, an elevated number of CD8⁺ T_{SCM} after immunosuppressive treatment was associated with treatment failure and subsequent disease relapse⁶³. Elevated quantities of T_{SCM} were also noted in patients with uveitis, but not with systemic lupus erythematosus, an immune-mediated disease primarily characterized by autoreactive humoral responses⁶³. Further pointing towards a role of T_{SCM} in the pathogenesis of autoimmune diseases and other illnesses of the lymphatic system, a recent genome-wide association study found a strong association between genetic polymorphisms affecting susceptibility to juvenile idiopathic arthritis or chronic lymphocytic leukemia, and the frequency of CD4⁺ T_{SCM}²². How T_{SCM} can influence autoimmune diseases will have to be studied in dedicated investigations, but based on current knowledge it is reasonable to hypothesize that long-lasting autoreactive or abnormally activated T_{SCM} may induce self-renewing inflammatory cellular responses that are responsible for the durable, and in most cases life-long persistence of such diseases⁶⁴. The possible role of T_{SCM} in other diseases with profound disturbance of cellular immune

responses, such as autoimmune hepatitis, thyroiditis, type I diabetes and certain types of glomerulonephritis, are currently unknown but represent a high priority area of future research.

In addition to their role in autoimmunity, T_{SCM} may have a distinct role in viral diseases in which T cells represent the predominant targets, such as infections caused by CD4⁺ T-cell tropic retroviruses. Notably, work in the context of HIV-1 infection has shown that CD4⁺ T_{SCM} can effectively support both productive viral replication and a transcriptionally-silent form of infection⁶⁵. Moreover, by infecting long-lived CD4⁺ T_{SCM}, HIV-1 is able to exploit their stemness to establish an extremely durable, self-renewing viral reservoir that can persist for decades despite ART, and continuously replenish virally-infected cells, perpetuating a disease they are meant to restrict⁶⁶. Indeed, the half-life of HIV-1-infected T_{SCM} in ART-treated individuals has been estimated to last for 277 months, a time period significantly longer than that observed for viral reservoirs established in more short-lived T-cell populations⁶⁷. In line with these observations, phylogenetic studies demonstrated close associations between viruses circulating early after HIV-1 infection and viral sequences isolated from CD4⁺ T_{SCM} after almost a decade of suppressive ART⁶⁶. Notably, the ability to use CD4⁺ T_{SCM} as a long-term viral reservoir also seems to occur in individuals infected with HTLV-1, a retrovirus related to HIV-1 that is the primary cause of adult T-cell leukemia (ATL). Emerging data indicate that transformed, HTLV-1 infected CD4⁺ T_{SCM} can act as progenitors for dominant circulating ATL clones, and efficiently repopulate ATL clones upon transplantation in animal models⁶⁸ suggesting that they can serve as a cancer stem cell population responsible for propagating and maintaining HTLV-1 infected malignant cells.

Targeting T_{SCM} cells for therapy

Harnessing T_{SCM} cells for adoptive T-cell therapy

The extreme longevity, the robust proliferative potential and the capacity to reconstitute a wide-ranging diversity of the T-cell compartment make T_{SCM} an ideal cell population to employ in adoptive immunotherapy (Fig. 2). Driven by the growing success of clinical trials based on the transfer of naturally occurring and genetically-engineered tumor-reactive T lymphocytes, adoptive immunotherapies are rapidly becoming a real therapeutic option for patients with cancer^{69,70}. Although these regimens can induce complete and durable tumor regressions in patients with advanced cancer, current response rates remain mostly inadequate underscoring the need for further improvements^{69,70}. There is now extensive evidence indicating that objective responses strongly correlate with the level of T-cell engraftment and peak of expansion earlier after transfer^{71–77}. T-cell persistence, though not strictly indispensable in certain conditions^{72–75,78}, has also been associated with the likelihood of objective responses in numerous trials^{76,77,79–83} and might be required to sustain durable remissions⁸⁴. These parameters are considerably influenced by the composition of the infused T-cell product as T-cell subsets differ widely in terms of proliferative capacity, immune reconstitution and long-term survival^{10,85}. Indeed, the administration of cells with longer telomeres^{81,86} or cell products comprising higher fractions of CD62L⁺, CD28⁺ or CD27⁺ T cells has been shown to correlate with objective tumor responses in patients^{81,86–88}, suggesting that less-differentiated T cells are

therapeutically superior to T_{TE}. Notably, the engraftment and expansion of T cells engineered to express a CD19-specific CAR³⁹ or a suicide gene³⁵ correlated with the frequency of infused CD8⁺CD45RA⁺CCR7⁺ T_{SCM}. Adoptive transfer experiments in mice using defined T-cell subsets have formally demonstrated that the infusion of less-differentiated CD62L⁺ T-cell populations results in enhanced T-cell engraftment, expansion and persistence, ultimately leading to more profound and durable tumor regressions^{18,19,89–93}. Consistent with the developmental hierarchy, minimally differentiated T_{SCM} mediate more potent antitumor responses than T_{CM}, which in turn are more effective than highly differentiated T_{EM}^{18,19,94}. Some level of plasticity, however, must be granted to the hierarchical model of memory T-cell differentiation. In NHP, genetically-engineered CMV-specific effectors derived from purified T_{CM} proved superior to effectors derived from T_{EM} in terms of *in vivo* expansion and persistence, showing that even after *in vitro* manipulation and apparently a similar degree of terminal differentiation, T cells maintain some characteristics of the subset of origin, and can possibly, at least in part, revert to that original phenotype and function⁹⁵.

Despite overwhelming preclinical data indicating a therapeutic advantage to transferring tumor-reactive CD62L⁺ T-cell subsets^{18,19,89–93}, clinical trials have largely employed unselected intratumoral or peripheral blood mononuclear cell (PBMC)-derived T-cell populations. Tumor infiltrating lymphocytes are typically in a state of terminal differentiation and functional exhaustion making the isolation of early memory T-cell subsets impractical^{96,97}. However, the selection of less-differentiated T-cell subsets becomes realistic and desirable in the context of immunotherapies aiming at conferring tumor reactivity to circulating T cells *via* TCR or CAR gene-engineering. The isolation of less-differentiated T-cell populations also has the advantage of reproducibly generating more consistent and defined T-cell products. Indeed, PBMC composition can vary significantly between individuals as a consequence of age⁹⁸, pathogen exposure⁹⁹, and prior systemic treatments¹⁰⁰. Moreover, unselected populations containing high proportions of T_{EM} and effector cells might fail to generate viable clinical products due to poor *in vitro* cell expansion¹⁰¹. Recently, two clinical trials in which CD19-specific CAR T cells were generated from isolated T_{CM} have been reported^{84,102,103}. This strategy led to the generation of infusion products comprising significantly more T_{EM} than those originating from unselected PBMC indicating that, in the absence of culture conditions restraining T-cell differentiation^{18,104–108}, the benefit of depleting highly-differentiated T cell subsets is outweighed by the concomitant removal of naïve and T_{SCM}¹⁰². Notwithstanding the reduction of less-differentiated T-cell subsets, the rates of objective remissions in acute lymphoblastic leukemia (ALL) patients were comparable to trials using unselected T-cell populations^{72,73,76,102,109,110}. Whether differences in manufacturing and T-cell product composition will affect rates and duration of clinical responses in other diseases and settings remains to be shown.

So far, the clinical exploitation of T_{SCM} has been hindered by their relative paucity in the circulation^{19,20} and the lack – until recently – of robust, clinical-grade manufacturing protocols capable of generating and maintaining this cell type *in vitro*. These strategies rely on programming and redirecting T_{SCM} from naïve-like T cells isolated from PBMC^{23,111} (Fig. 2). Although the isolation of naïve T cells adds complexity to the manufacturing

process, it is a critical step because the presence of more differentiated T-cell subsets during naïve T-cell stimulation accelerates naïve T-cell differentiation into T_{EM} and T_{TE} cells¹¹². It should also be considered that purifying large numbers of specific cell subsets over multiple parameters under GMP conditions is becoming increasingly accessible thanks to recent developments in clinical cell sorting technologies^{85,113}. IL-7 and IL-15 have successfully been used to generate tumor-redirection or suicide gene-modified T_{SCM} from naïve cell precursors²³ (Fig. 2). IL-7 is essential for the development of these cells^{23,114}, while IL-15 primarily sustains their expansion²³. IL-7 and IL-15-programmed T_{SCM} possess a core gene signature of naturally occurring T_{SCM}, display an enhanced proliferative capacity compared to other T-cell subsets and are uniquely capable of expanding and mediating GVHD upon serial transplantation²³. This cytokine combination could also be employed to generate large numbers of TCR gene-edited T_{SCM} by combining Zinc Finger Nuclease sets specific for the endogenous TCR gene loci with lentiviral vectors encoding tumor-specific TCRs¹¹⁵ (Fig. 2). Moreover, the ability of IL-7 and IL-15 to support the formation and expansion of T_{SCM} makes it an ideal strategy to generate T_{SCM} without the need to redirect their specificity. This may be particularly suitable for the generation of virus-specific T_{SCM} for the treatment and prevention of life-threatening infections after transplantation (Fig. 2) as infection control can be obtained by transferring relatively small numbers of virus-specific memory cells¹¹⁶. A demonstration that IL-7 and IL-15 could be successfully employed to generate and expand virus-specific T_{SCM} starting from isolated naïve-like cells was recently provided by Volk and colleagues¹¹⁷. This protocol could also be adapted to generate CAR-modified virus-specific T_{SCM}, which may lower the risk of GVHD given the restricted TCR repertoire and exhibit additional proliferative and survival advantages as result of the *in vivo* triggering of the native virus-specific TCRs by antigens from persistent viruses^{80,118}. Another clinical-grade strategy promoting the generation of tumor-reactive T_{SCM} is based on the activation of naïve-like lymphocytes in the presence of IL-7, IL-21 and the WNT agonist TWS119¹¹¹. Although both IL-15^{119,120} and IL-21¹²¹⁻¹²³ have been implicated in the generation and maintenance of memory T cells, IL-21 is more effective in restraining T-cell differentiation¹⁰⁵ due to its specific ability to activate STAT3 signaling¹²⁴ and to sustain the expression of WNT- β -catenin transcription factors *TCF7* and *LEF1*¹⁰⁵. TWS119 provides a synergistic effect with IL-21 to induce maximal expression of *TCF7* and *LEF1* by stabilizing β -catenin¹¹¹. CAR-modified T_{SCM} generated under these culture conditions are phenotypically, functionally, and transcriptionally equivalent to their naturally occurring counterparts¹¹¹. Moreover, they exhibit metabolic features characteristic of long-lived memory T cells such as a high spare respiratory capacity¹²⁵ and low glycolytic metabolism¹²⁶. Although these culture conditions profoundly inhibit T-cell proliferation, T_{SCM} can be efficiently redirected against a tumor antigen and expanded to clinically relevant numbers¹¹¹. More importantly, CAR-modified CD8⁺ T_{SCM} mediated superior and more durable anti-tumor responses than cells generated with protocols currently employed in clinical trials¹¹¹. CAR-modified T_{SCM} may also provide an attractive approach for immunotherapy in the setting of non-malignant diseases, such as HIV-1 infection or other chronic viral illnesses^{127,128} (Fig. 2). Altogether, these studies provide both a strong scientific rationale and practical methodologies for the rapid advancement of T_{SCM} in human clinical trials of adoptive immunotherapy¹²⁹.

Disrupting T_{SCM} cell reservoirs in retroviral infections and autoimmune diseases

The emerging role of CD4⁺ T_{SCM} in the pathogenesis of chronic viral infections such as HIV-1 and HTLV-1 infection may also offer novel opportunities to prevent, treat or cure these diseases. In the context of HIV-1 infection, specific interventions that eliminate HIV-1-infected CD4⁺ T_{SCM} may allow for the destabilization of HIV-1 reservoirs by reducing the number of HIV-1-infected source cells from which new HIV-1⁺ viral and cellular progeny can continuously originate, despite suppressive ART. As the molecular programs governing the stem cell-like behavior of T_{SCM} continue to be understood, new molecules regulating proliferation and self-renewal of T_{SCM} may represent attractive targets for reducing viral persistence in CD4⁺ T_{SCM}. For instance, WNT-β-catenin signaling has been identified as a key driver for the homeostasis of T_{SCM}¹⁸, and pharmaceutical inhibition of this pathway may therefore translate into a more limited ability of HIV-1 to use the T_{SCM} compartment for maintaining survival of virally-infected cells (Fig. 2). This approach may be facilitated by the availability of existing pharmacological inhibitors of WNT-β-catenin designed to target cancer stem cells¹³⁰. Although such a strategy might be not entirely specific for eliminating HIV-1-specific CD4⁺ T_{SCM}, advances in nanotechnology may allow for selective delivery of WNT-β-catenin antagonists or short hairpin RNAs targeting key mediators of WNT signaling to CD4⁺ T cells or virally-infected cells *via* nanoparticles or aptamer-based targeting systems^{131,132} (Fig. 2). Similar strategies are also conceivable to target HTLV-1-infected T_{SCM} in the setting of ATL or to disrupt long-lasting reservoirs of autoreactive T_{SCM} in autoimmune diseases. Additionally, recent advances in *ex-vivo* gene editing may allow the design of CD4⁺ T_{SCM} that are intrinsically resistant to HIV-1, through e. g. targeted deletion of the chemokine receptor CCR5, which is necessary for viral entry¹³³, thus mimicking the CCR5 Δ32 mutation known to confer resistance to HIV-1 infection¹³⁴ (Fig. 2). Such a population of long-lasting, HIV-1-resistant CD4⁺ T cells could be used in adoptive immunotherapy strategies to establish a durable cellular immune system that is no longer able to support HIV-1 infection, and may allow for drug-free remission of HIV-1 infection.

Concluding Remarks

T_{SCM} are rare antigen-experienced T cells, likely generated directly from naïve lymphocytes and endowed with long-term self-renewal capacity and multipotency. Compelling evidence in mice, NHP, and humans points towards a scenario in which T_{SCM} represent the apex of the memory T-cell differentiation tree. Their longevity and their capacity to reconstitute the entire heterogeneity of the T-cell memory compartment entail a double edged – protective or pathogenic – role for T_{SCM} in human diseases. The increasingly recognized protective role of T_{SCM} in acute and chronic infections makes them optimal candidates for therapeutic exploitation in vaccination and adoptive T-cell therapy against infectious diseases and cancer. Conversely, their relevance in the pathogenesis of autoimmunity, adult T-cell leukemia and HIV-1, makes T_{SCM} an attractive target to tame for these pathological conditions. Several issues regarding T_{SCM} biology remain to be addressed: characterization of their metabolic requirements, epigenetic and transcriptional programs, and anatomical niches (Box 1) will possibly guide innovative T_{SCM}-based therapeutic interventions for human diseases.

T_{SCM} epigenetic and transcriptional programs.

Genome-wide transcriptomic analyses of whole^{19,135} and yellow fever-specific T_{SCM}^{36,37} have shown a high relatedness between these cells and central memory T cells (T_{CM}). These findings suggest that the majority of signaling pathways and transcriptional factors that shape the development and maintenance of T_{CM} might be to a certain degree involved in the regulation of T_{SCM}. This reasoning is exemplified by the demonstration that WNT- β -catenin signaling, which is essential for T_{CM} formation and long-term survival^{141–144}, is also critical for the generation of T_{SCM}^{18,19,111}. Likewise, tempering mTOR signaling has been shown to enhance the development of both T_{CM}^{145,146} and T_{SCM}¹³⁵. Whether specific transcriptional networks are uniquely activated to influence T_{SCM} fate is unknown. It is also currently unclear what is the role of CD95-FASL signaling in T_{SCM} homeostasis. The epigenetic programs in T_{SCM} remain largely undefined. Emerging genome-wide analysis of histone methylation on two histone H3 lysine residues (H3K4me3 and H3K27me3) in naïve and *in vitro*-generated murine CD8⁺ T cell subsets have revealed that chromatin accessibility is mostly regulated in a progressive fashion further supporting a hierarchical model of T-cell differentiation, in which T_{SCM} represent the least differentiated antigen-experienced T cell subset¹³⁶.

T_{SCM} metabolism.

A growing body of work has recently highlighted the importance of cell metabolism in regulating the activity and fate commitment of T lymphocytes¹⁴⁷. Fatty acid oxidation, increased mitochondrial biomass and spare respiratory capacity (SRC) have been shown to support the development of memory T cells and confer on them a bioenergetic advantage necessary to sustain rapid recall responses^{125,148}. Conversely, aerobic glycolysis has been associated with the formation of short-lived terminally differentiated effector cells and defects in the establishment of T cell memory¹²⁶. Emerging findings indicate that naturally-occurring and *in vitro*-generated human T_{SCM} also exhibit the prototypical ‘metabolic signature’ of memory cells with reduced glycolytic flux, preferential lipid oxidative metabolism, and high SRC^{111,135}. Recently, HSC and T cell stemness have been linked to presence of decreased mitochondrial membrane potential (Ψ m)¹⁴⁹. Consistent with these findings, T_{SCM} display lower Ψ m than other antigen-experienced T cell subsets, including T_{CM}^{135,149}. Whether T_{SCM} maintain fused mitochondrial networks with tight cristae organization, which have been shown to facilitate electron transport chain activity in conventional memory T cells¹⁵⁰ remains to be determined. Future area of research also include a more global characterization of the T_{SCM} metabolome and a deeper understanding of the role of amino acids in T_{SCM} metabolism and function.

T_{SCM} anatomical niches.

Stem cell niches are instrumental in regulating stem cell behavior and tissue homeostasis¹⁵¹. Specialized niches in the bone marrow provide not only physical support but also soluble factors and cellular interactions that guide HSCs’ decision to either self-renew or differentiate¹⁵¹. Increasing evidence has recently underscored the critical role of the bone marrow also in sustaining life-long persistence of conventional memory T cells^{152–155}. Whether the bone marrow can similarly serve as a niche for T_{SCM} is a fundamental question

that needs to be addressed. Alternatively, it might be evaluated whether, akin to naïve T cells¹⁵⁶, T_{SCM} rely on homeostatic cues provided by fibroblastic reticular cell niches within T-cell zones of secondary lymphoid organs. Finally, it would be critical to characterize cell contact-dependent cross-talk, cytokine networks and metabolite constituents regulating T_{SCM} differentiation and function in their niches.

Acknowledgments

Funding: This work was supported by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research (ZIABC011480), the 2014 US National Institutes of Health (NIH) Bench-to-Bedside Award, the NIH grants AI098487, AI106468, AI114235, AI117841, AI120008, AI124776, the Cancer Research Institute (NY), the Ludwig Cancer Research (NY), the Swiss Cancer League (3507–08-2014), the Swiss National Science Foundation (320030_152856, CRSII3_160708), the SwissTransMed (KIP 18), the Italian Association for Cancer Research and the SUPERSIST (EU-FP7 project).

Timeline: T-cell stemness and TSCM: milestones and key discoveries

T_{SCM}	T memory stem cells
GVHD	graft versus host disease
HIV-1	Human Immunodeficiency Virus-type 1
SIV	Simian Immunodeficiency Virus
HTLV-1	, Human T-cell lymphotropic virus type 1
CAR	Chimeric antigen receptor

References

1. Thucydides & Hobbes T Peloponnesian Warre, (Charles Harper, London, 1676).
2. Sallusto F, Lanzavecchia A, Araki K & Ahmed R From vaccines to memory and back. *Immunity* 33, 451–463 (2010). [PubMed: 21029957]
3. Ahmed R, Bevan MJ, Reiner SL & Fearon DT The precursors of memory: models and controversies. *Nature reviews. Immunology* 9, 662–668 (2009).
4. Restifo NP & Gattinoni L Lineage relationship of effector and memory T cells. *Current opinion in immunology* (2013).
5. Demkowicz WE, Jr., Littau RA, Wang J & Ennis FA Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. *J Virol* 70, 2627–2631 (1996). [PubMed: 8642697]
6. Hammarlund E, et al. Duration of antiviral immunity after smallpox vaccination. *Nature medicine* 9, 1131–1137 (2003).
7. Fearon DT, Manders P & Wagner SD Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. *Science* 293, 248–250 (2001). [PubMed: 11452114]
8. Luckey CJ, et al. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. *Proceedings of the National Academy of Sciences of the United States of America* 103, 3304–3309 (2006). [PubMed: 16492737]
9. CioCCA ML, Barnett BE, Burkhardt JK, Chang JT & Reiner SL Cutting edge: Asymmetric memory T cell division in response to rechallenge. *J Immunol* 188, 4145–4148 (2012). [PubMed: 22467651]
10. Gattinoni L, Klebanoff CA & Restifo NP Paths to stemness: building the ultimate antitumour T cell. *Nature reviews. Cancer* 12, 671–684 (2012). [PubMed: 22996603]
11. Chattopadhyay PK, Gierahn TM, Roederer M & Love JC Single-cell technologies for monitoring immune systems. *Nature immunology* 15, 128–135 (2014). [PubMed: 24448570]

12. Hamann D, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. *The Journal of experimental medicine* 186, 1407–1418 (1997). [PubMed: 9348298]
13. Sallusto F, Lenig D, Forster R, Lipp M & Lanzavecchia A Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 401, 708–712 (1999). [PubMed: 10537110]
14. Zhang Y, Joe G, Hexner E, Zhu J & Emerson SG Host-reactive CD8+ memory stem cells in graft-versus-host disease. *Nature medicine* 11, 1299–1305 (2005).
15. Long HM, et al. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. *The Journal of experimental medicine* 210, 933–949 (2013). [PubMed: 23569328]
16. Miller JD, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. *Immunity* 28, 710–722 (2008). [PubMed: 18468462]
17. Akondy RS, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. *J Immunol* 183, 7919–7930 (2009). [PubMed: 19933869]
18. Gattinoni L, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. *Nature medicine* 15, 808–813 (2009).
19. Gattinoni L, et al. A human memory T cell subset with stem cell-like properties. *Nature medicine* 17, 1290–1297 (2011).
20. Lugli E, et al. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. *Nature protocols* 8, 33–42 (2013). [PubMed: 23222456]
21. Di Benedetto S, et al. Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. *Biogerontology* 16, 631–643 (2015). [PubMed: 25732234]
22. Roederer M, et al. The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis. *Cell* 161, 387–403 (2015). [PubMed: 25772697]
23. Cieri N, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. *Blood* 121, 573–584 (2013). [PubMed: 23160470]
24. Lugli E, et al. Superior T memory stem cell persistence supports long-lived T cell memory. *The Journal of clinical investigation* (2013).
25. Simons BD & Clevers H Strategies for homeostatic stem cell self-renewal in adult tissues. *Cell* 145, 851–862 (2011). [PubMed: 21663791]
26. Wherry EJ, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. *Nature immunology* 4, 225–234 (2003). [PubMed: 12563257]
27. Graef P, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. *Immunity* 41, 116–126 (2014). [PubMed: 25035956]
28. Gattinoni L Memory T cells officially join the stem cell club. *Immunity* 41, 7–9 (2014). [PubMed: 25035947]
29. Gerlach C, et al. Heterogeneous differentiation patterns of individual CD8+ T cells. *Science* 340, 635–639 (2013). [PubMed: 23493421]
30. Buchholz VR, et al. Disparate individual fates compose robust CD8+ T cell immunity. *Science* 340, 630–635 (2013). [PubMed: 23493420]
31. Lanzavecchia A & Sallusto F Progressive differentiation and selection of the fittest in the immune response. *Nature reviews. Immunology* 2, 982–987 (2002).
32. Joshi NS, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. *Immunity* 27, 281–295 (2007). [PubMed: 17723218]
33. Cieri N, et al. Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. *Blood* 125, 2865–2874 (2015). [PubMed: 25736310]
34. Roberto A, et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. *Blood* 125, 2855–2864 (2015). [PubMed: 25742699]
35. Oliveira G, et al. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. *Science translational medicine* 7, 317ra198 (2015).
36. Fuertes Marraco SA, et al. Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile upon yellow fever vaccination. *Science translational medicine* 7, 282ra248 (2015).

37. Fuertes Marraco SA, Soneson C, Delorenzi M & Speiser DE Genome-wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever vaccination in humans. *Genom Data* 5, 297–301 (2015). [PubMed: 26484272]
38. Biasco L, et al. In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. *Science translational medicine* 7, 273ra213 (2015).
39. Xu Y, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. *Blood* 123, 3750–3759 (2014). [PubMed: 24782509]
40. Vigano S, et al. Prolonged Antiretroviral Therapy Preserves HIV-1-Specific CD8 T Cells with Stem Cell-Like Properties. *J Virol* 89, 7829–7840 (2015). [PubMed: 25995260]
41. Axelsson-Robertson R, Ju JH, Kim HY, Zumla A & Maeurer M Mycobacterium tuberculosis-specific and MHC class I-restricted CD8+ T-cells exhibit a stem cell precursor-like phenotype in patients with active pulmonary tuberculosis. *Int J Infect Dis* 32, 13–22 (2015). [PubMed: 25809750]
42. Mateus J, et al. Low frequency of circulating CD8+ T stem cell memory cells in chronic chagasic patients with severe forms of the disease. *PLoS Negl Trop Dis* 9, e3432 (2015). [PubMed: 25569149]
43. Ahmed R & Akondy RS Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. *Immunology and cell biology* 89, 340–345 (2011). [PubMed: 21301482]
44. Speiser DE, et al. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? *Nature reviews. Immunology* 14, 768–774 (2014).
45. Utzschneider DT, et al. T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. *Immunity* 45, 415–427 (2016). [PubMed: 27533016]
46. Im SJ, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature* 537, 417–421 (2016). [PubMed: 27501248]
47. Ribeiro SP, et al. The CD8(+) memory stem T cell (T(SCM)) subset is associated with improved prognosis in chronic HIV-1 infection. *J Virol* 88, 13836–13844 (2014). [PubMed: 25253339]
48. Cartwright EK, et al. Divergent CD4+ T Memory Stem Cell Dynamics in Pathogenic and Nonpathogenic Simian Immunodeficiency Virus Infections. *J Immunol* (2014).
49. Klatt NR, et al. Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. *PLoS pathogens* 10, e1004345 (2014). [PubMed: 25167059]
50. Cartwright EK, et al. Initiation of antiretroviral therapy restores CD4+ TSCM homeostasis in SIV-infected macaques. *J Virol* (2016).
51. Calascibetta F, et al. Antiretroviral therapy in SIV-infected sooty mangabeys: implications for AIDS pathogenesis. *J Virol* (2016).
52. Speiser DE, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. *The Journal of clinical investigation* 115, 739–746 (2005). [PubMed: 15696196]
53. Melero I, et al. Therapeutic vaccines for cancer: an overview of clinical trials. *Nature reviews. Clinical oncology* 11, 509–524 (2014).
54. De Gregorio E & Rappuoli R Vaccines for the future: learning from human immunology. *Microb Biotechnol* 5, 149–155 (2012). [PubMed: 21880117]
55. Chang JT, Wherry EJ & Goldrath AW Molecular regulation of effector and memory T cell differentiation. *Nature immunology* 15, 1104–1115 (2014). [PubMed: 25396352]
56. Pham NL, Badovinac VP & Harty JT A default pathway of memory CD8 T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation. *J Immunol* 183, 2337–2348 (2009). [PubMed: 19635915]
57. Park CO & Kupper TS The emerging role of resident memory T cells in protective immunity and inflammatory disease. *Nature medicine* 21, 688–697 (2015).
58. Mackay LK, et al. T-box Transcription Factors Combine with the Cytokines TGF-beta and IL-15 to Control Tissue-Resident Memory T Cell Fate. *Immunity* 43, 1101–1111 (2015). [PubMed: 26682984]

59. Zhang N & Bevan MJ Transforming growth factor-beta signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. *Immunity* 39, 687–696 (2013). [PubMed: 24076049]
60. Jameson SC & Masopust D Diversity in T cell memory: an embarrassment of riches. *Immunity* 31, 859–871 (2009). [PubMed: 20064446]
61. Farber DL, Yudanin NA & Restifo NP Human memory T cells: generation, compartmentalization and homeostasis. *Nature reviews. Immunology* 14, 24–35 (2014).
62. Gattinoni L The dark side of T memory stem cells. *Blood* 125, 3519–3520 (2015). [PubMed: 26045590]
63. Hosokawa K, et al. Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. *J Immunol* 196, 1568–1578 (2016). [PubMed: 26764034]
64. Monti P, Heninger AK & Bonifacio E Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. *Curr Diab Rep* 9, 113–118 (2009). [PubMed: 19323955]
65. Tabler CO, et al. CD4+ memory stem cells are infected by HIV-1 in a manner regulated in part by SAMHD1 expression. *J Virol* 88, 4976–4986 (2014). [PubMed: 24554663]
66. Buzon MJ, et al. HIV-1 persistence in CD4(+) T cells with stem cell-like properties. *Nature medicine* 20, 139–142 (2014).
67. Jaafoura S, et al. Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4(+) memory T Cells. *Nature communications* 5, 5407 (2014).
68. Nagai Y, et al. T memory stem cells are the hierarchical apex of adult T-cell leukemia. *Blood* (2015).
69. Rosenberg SA & Restifo NP Adoptive cell transfer as personalized immunotherapy for human cancer. *Science* 348, 62–68 (2015). [PubMed: 25838374]
70. June CH, Riddell SR & Schumacher TN Adoptive cellular therapy: a race to the finish line. *Science translational medicine* 7, 280ps287 (2015).
71. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* 298, 850–854 (2002). [PubMed: 12242449]
72. Brentjens RJ, et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. *Science translational medicine* 5, 177ra138 (2013).
73. Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *Lancet* 385, 517–528 (2015). [PubMed: 25319501]
74. Kochenderfer JN, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 33, 540–549 (2015). [PubMed: 25154820]
75. Brudno JN, et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* (2016).
76. Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *The New England journal of medicine* 371, 1507–1517 (2014). [PubMed: 25317870]
77. Porter DL, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Science translational medicine* 7, 303ra139 (2015).
78. Robbins PF, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. *Clinical cancer research : an official journal of the American Association for Cancer Research* 21, 1019–1027 (2015). [PubMed: 25538264]
79. Robbins PF, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. *J Immunol* 173, 7125–7130 (2004). [PubMed: 15585832]

80. Pule MA, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nature medicine* 14, 1264–1270 (2008).
81. Rosenberg SA, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clinical cancer research : an official journal of the American Association for Cancer Research* 17, 4550–4557 (2011). [PubMed: 21498393]
82. Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Science translational medicine* 3, 95ra73 (2011).
83. Stevanovic S, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 33, 1543–1550 (2015). [PubMed: 25823737]
84. Turtle CJ, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. *Science translational medicine* 8, 355ra116 (2016).
85. Busch DH, Frassle SP, Sommermeyer D, Buchholz VR & Riddell SR Role of memory T cell subsets for adoptive immunotherapy. *Seminars in immunology* 28, 28–34 (2016). [PubMed: 26976826]
86. Zhou J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. *J Immunol* 175, 7046–7052 (2005). [PubMed: 16272366]
87. Huang J, et al. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. *J Immunol* 176, 7726–7735 (2006). [PubMed: 16751420]
88. Louis CU, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood* 118, 6050–6056 (2011). [PubMed: 21984804]
89. Gattinoni L, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. *The Journal of clinical investigation* 115, 1616–1626 (2005). [PubMed: 15931392]
90. Klebanoff CA, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. *Proceedings of the National Academy of Sciences of the United States of America* 102, 9571–9576 (2005). [PubMed: 15980149]
91. Hinrichs CS, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. *Proceedings of the National Academy of Sciences of the United States of America* 106, 17469–17474 (2009). [PubMed: 19805141]
92. Wang X, et al. Comparison of naive and central memory derived CD8 effector cell engraftment fitness and function following adoptive transfer. *Oncoimmunology* 5, e1072671 (2016). [PubMed: 26942092]
93. Sommermeyer D, et al. Chimeric antigen receptor-modified T cells derived from defined CD8 and CD4 subsets confer superior antitumor reactivity in vivo. *Leukemia* (2015).
94. Klebanoff CA, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. *Clinical cancer research : an official journal of the American Association for Cancer Research* 17, 5343–5352 (2011). [PubMed: 21737507]
95. Berger C, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. *The Journal of clinical investigation* 118, 294–305 (2008). [PubMed: 18060041]
96. Baitsch L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. *The Journal of clinical investigation* 121, 2350–2360 (2011). [PubMed: 21555851]
97. Gros A, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. *The Journal of clinical investigation* (2014).
98. Lugli E, et al. Subject classification obtained by cluster analysis and principal component analysis applied to flow cytometric data. *Cytometry A* 71, 334–344 (2007). [PubMed: 17352421]
99. Appay V, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. *Nature medicine* 8, 379–385 (2002).

100. Mackall CL, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. *Blood* 89, 3700–3707 (1997). [PubMed: 9160675]
101. Singh N, Perazzelli J, Grupp SA & Barrett DM Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. *Science translational medicine* 8, 320ra323 (2016).
102. Turtle CJ, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *The Journal of clinical investigation* (2016).
103. Wang X, et al. Phase I studies of central-memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL. *Blood* (2016).
104. Li Q, et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. *Immunity* 34, 541–553 (2011). [PubMed: 21511183]
105. Hinrichs CS, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. *Blood* 111, 5326–5333 (2008). [PubMed: 18276844]
106. van der Waart AB, et al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. *Blood* 124, 3490–3500 (2014). [PubMed: 25336630]
107. Crompton JG, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. *Cancer research* 75, 296–305 (2015). [PubMed: 25432172]
108. Gattinoni L, Klebanoff CA & Restifo NP Pharmacologic induction of CD8+ T cell memory: better living through chemistry. *Science translational medicine* 1, 11ps12 (2009).
109. Davila ML, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Science translational medicine* 6, 224ra225 (2014).
110. Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *The New England journal of medicine* 368, 1509–1518 (2013). [PubMed: 23527958]
111. Sabatino M, et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. *Blood* (2016).
112. Klebanoff CA, et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. *The Journal of clinical investigation* 126, 318–334 (2016). [PubMed: 26657860]
113. Klebanoff CA, Gattinoni L & Restifo NP Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? *J Immunother* 35, 651–660 (2012). [PubMed: 23090074]
114. Ding ZC, et al. IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells. *Oncoimmunology* 5, e1171445 (2016). [PubMed: 27471650]
115. Provasi E, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. *Nature medicine* 18, 807–815 (2012).
116. Stemmerger C, et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. *Blood* 124, 628–637 (2014). [PubMed: 24855206]
117. Schmuck-Henneresse M, et al. Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency. *J Immunol* 194, 5559–5567 (2015). [PubMed: 25917088]
118. Terakura S, et al. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. *Blood* 119, 72–82 (2012). [PubMed: 22031866]
119. Becker TC, et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. *The Journal of experimental medicine* 195, 1541–1548 (2002). [PubMed: 12070282]
120. Schluns KS, Williams K, Ma A, Zheng XX & Lefrancois L Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. *J Immunol* 168, 4827–4831 (2002). [PubMed: 11994430]
121. Yi JS, Du M & Zajac AJ A vital role for interleukin-21 in the control of a chronic viral infection. *Science* 324, 1572–1576 (2009). [PubMed: 19443735]
122. Frohlich A, et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. *Science* 324, 1576–1580 (2009). [PubMed: 19478140]

123. Yi JS, Ingram JT & Zajac AJ IL-21 deficiency influences CD8 T cell quality and recall responses following an acute viral infection. *J Immunol* 185, 4835–4845 (2010). [PubMed: 20844201]
124. Cui W, Liu Y, Weinstein JS, Craft J & Kaech SM An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. *Immunity* 35, 792–805 (2011). [PubMed: 22118527]
125. van der Windt GJ, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. *Immunity* 36, 68–78 (2012). [PubMed: 22206904]
126. Sukumar M, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. *The Journal of clinical investigation* 123, 4479–4488 (2013). [PubMed: 24091329]
127. Liu L, et al. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. *J Virol* 89, 6685–6694 (2015). [PubMed: 25878112]
128. Ali A, et al. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly-Neutralizing Antibodies. *J Virol* (2016).
129. Gattinoni L & Restifo NP Moving T memory stem cells to the clinic. *Blood* 121, 567–568 (2013). [PubMed: 23349370]
130. Kahn M Can we safely target the WNT pathway? *Nature reviews. Drug discovery* 13, 513–532 (2014). [PubMed: 24981364]
131. Ramishetti S, et al. Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. *ACS nano* 9, 6706–6716 (2015). [PubMed: 26042619]
132. Zhou J, et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. *Nucleic acids research* 37, 3094–3109 (2009). [PubMed: 19304999]
133. Tebas P, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. *N Engl J Med* 370, 901–910 (2014). [PubMed: 24597865]
134. Dragic T, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 [see comments]. *Nature* 381, 667–673 (1996). [PubMed: 8649512]
135. Scholz G, et al. Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells. *EBioMedicine* 4, 50–61 (2016). [PubMed: 26981571]
136. Crompton JG, et al. Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. *Cell Mol Immunol* 13, 502–513 (2016). [PubMed: 25914936]
137. Chang JT, et al. Asymmetric proteasome segregation as a mechanism for unequal partitioning of the transcription factor T-bet during T lymphocyte division. *Immunity* 34, 492–504 (2011). [PubMed: 21497118]
138. Lin WH, et al. Asymmetric PI3K Signaling Driving Developmental and Regenerative Cell Fate Bifurcation. *Cell reports* 13, 2203–2218 (2015). [PubMed: 26628372]
139. Verbist KC, et al. Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. *Nature* 532, 389–393 (2016). [PubMed: 27064903]
140. Pollizzi KN, et al. Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation. *Nature immunology* 17, 704–711 (2016). [PubMed: 27064374]
141. Jeannot G, et al. Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. *Proceedings of the National Academy of Sciences of the United States of America* 107, 9777–9782 (2010). [PubMed: 20457902]
142. Zhou X, et al. Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. *Immunity* 33, 229–240. [PubMed: 20727791]
143. Zhao DM, et al. Constitutive activation of Wnt signaling favors generation of memory CD8 T cells. *J Immunol* 184, 1191–1199.
144. Boudousquie C, et al. Differences in the transduction of canonical Wnt signals demarcate effector and memory CD8 T cells with distinct recall proliferation capacity. *J Immunol* 193, 2784–2791 (2014). [PubMed: 25127860]
145. Araki K, et al. mTOR regulates memory CD8 T-cell differentiation. *Nature* 460, 108–112 (2009). [PubMed: 19543266]

146. Rao RR, Li Q, Odunsi K & Shrikant PA The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. *Immunity* 32, 67–78 (2010). [PubMed: 20060330]
147. Pearce EL, Poffenberger MC, Chang CH & Jones RG Fueling immunity: insights into metabolism and lymphocyte function. *Science* 342, 1242454 (2013). [PubMed: 24115444]
148. van der Windt GJ, et al. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. *Proceedings of the National Academy of Sciences of the United States of America* 110, 14336–14341 (2013). [PubMed: 23940348]
149. Sukumar M, et al. Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. *Cell metabolism* 23, 63–76 (2016). [PubMed: 26674251]
150. Buck MD, et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. *Cell* 166, 63–76 (2016). [PubMed: 27293185]
151. Morrison SJ & Spradling AC Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. *Cell* 132, 598–611 (2008). [PubMed: 18295578]
152. Di Rosa F Two Niches in the Bone Marrow: A Hypothesis on Life-long T Cell Memory. *Trends in immunology* (2016).
153. Alp OS, et al. Memory CD8 T cells colocalize with IL-7 stromal cells in bone marrow and rest in terms of proliferation and transcription. *European journal of immunology* (2015).
154. Becker TC, Coley SM, Wherry EJ & Ahmed R Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. *J Immunol* 174, 1269–1273 (2005). [PubMed: 15661882]
155. Mazo IB, et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. *Immunity* 22, 259–270 (2005). [PubMed: 15723813]
156. Takada K & Jameson SC Naïve T cell homeostasis: from awareness of space to a sense of place. *Nature reviews. Immunology* 9, 823–832 (2009).

Box 1:**T_{SCM} cell biology: outstanding questions**

Several questions regarding T_{SCM} biology have yet to be addressed. A major unresolved issue is how T_{SCM} physiologically form during the course of an infection and the impact of the strength of antigen stimulation. Is T_{SCM} fate immediately programmed at the time of naïve T cell priming or is it shaped throughout the number of antigen encounters and the diverse inflammatory environments that their progenies experience in the acute phase of the infection? A glimpse into T_{SCM} transcriptional and epigenetic landscapes^{19,36,37,135,136}, and early work exploring T_{SCM} metabolism^{111,135} have begun to shed light on the molecular and metabolic programs regulating T_{SCM} formation and homeostasis, but much ground remains to be covered. For instance, it is still unknown whether and to what extent asymmetric partitioning of key transcription factors^{137,138} and metabolic master regulators^{139,140} is programming T_{SCM} formation. Additionally, studies examining T_{SCM} anatomical niches are entirely missing. Progress in these area of investigation has been hampered to some extent by the rareness of T_{SCM} in the circulation, which is a limiting factor for epigenetic, proteomic and metabolomic studies. A major hurdle is the lack of mouse infection models capable of generating robust numbers of T_{SCM}, which so far has precluded researchers to precisely evaluate specific gene contributions to T_{SCM} physiology and physiopathology with genetic tools, and to image T_{SCM} dynamics in tissues by real-time *in vivo* microscopy.

Figure 1: Hierarchical model of human T-cell differentiation.

Following antigen priming, naïve T cells (T_N) progressively differentiate into diverse memory T-cell subpopulations and ultimately into terminally differentiated effector T cells (T_{TE}). T-cell subsets are distinguished by the combinatorial expression of the indicated surface markers. As T_N progressively differentiate into T_{TE} , they lose or acquire specific functional and metabolic attributes. T_{SCM} , T memory stem cell; T_{CM} , central memory T cell; T_{EM} , effector memory T cell; Ψ_m , mitochondrial membrane potential.

CD45RA	+	+	-	-	+
CD45RO	-	-	+	+	-
CCR7	+	+	+	-	-
CD62L	+	+	+	-	-
CD28	+	+	+	+/-	-
CD27	+	+	+	+/-	-
IL-7Rα	+	+	+	+/-	-
CXCR3	-	+	+	-	-
CD95	-	+	+	+	+
CD11a	-	+	+	+	+
IL-2Rβ	-	+	+	+	+
CD58	-	+	+	+	+
CD57	-	-	-	+/-	+

Figure 2: T_{SCM}-based therapeutic interventions for human diseases. T memory stem cells (T_{SCM}) can be either tamed (left panel) to treat T_{SCM}-driven diseases such as autoimmunity, T-cell leukemia and T-cell tropic infections or exploited (right panel) to potentiate T cell-based immunotherapies against cancer and infectious diseases. Left panel: WNT antagonists or short hairpin RNA (shRNA) targeting key molecules involved in WNT signaling such as T cell factor 7 (*TCF7*) could be used to disrupt long-lasting, self-renewing T_{SCM} reservoirs by driving them to differentiate into short-lived subsets such as effector memory T cells (T_{EM}). Nanoparticle or aptamer technology could be employed to specifically target CD4⁺ T cells or virally-infected T cells. Right panel: patient- or donor-derived naïve-like T cells can be used to generate and *in vitro* expand T_{SCM} with or without gene engineering. Gene modifications include the insertion of tumor or virus-specific chimeric antigen receptor (CAR) or T cell receptor (TCR) genes, tumor or virus-specific TCR gene editing, suicide gene transfer in the context of donor lymphocyte infusion following hematopoietic stem cell transplantation, and CCR5 deletion in the setting of

HIV-1 infection. Virus-specific T_{SCM} can also be expanded from the naturally-occurring antigen-specific TCR repertoire through *in vitro* sensitization protocols favoring the generation of T_{SCM}. T_N, naïve T cell; T_{CM}, central memory T cell; APC, antigen presenting cell.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript